BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Every scanner, the BH Indicator, insider and options flow, sector and industry rankings, the themes, the trading journal and the daily briefings from the Senior Analyst.
See plans →Breakouts Happen publishes market analysis and screening tools. Every idea, opinion and forecast on this site — stated or implied — is provided for informational purposes only and is not a recommendation to invest, trade or speculate in any market. Any position taken in light of the material published here is taken at your own risk, financial or otherwise. Breakouts Happen is not a registered investment advisor, and nothing on this site is an offer or solicitation to buy or sell any security.
Market data is delayed and provided for reference only. Past performance does not indicate future results.
Essential cookies for basic site functions, including your session.
Cookies for enhanced functionality, such as your theme preference.
Cookies to understand site usage and improve our service.
Cookies to improve site performance.